HUMANIGEN, INC
HUMANIGEN, INC (HGEN): 2 pipeline candidates · ~2 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.6 months
D/E -1.10 · 0% dilution
Lead: Preclinical
2 candidates
N/A
N/A
A transparent, data-derived signal for HUMANIGEN, INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$3.1M
Quarterly Burn
$7.1M
Runway
1.6 mo
Revenue
$221K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| ifabotuzumab | Preclinical |
| lenzilumab | Preclinical |
Frequently asked questions
How many drug candidates are in HUMANIGEN, INC's pipeline?
HUMANIGEN, INC (HGEN) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is HUMANIGEN, INC's lead drug candidate?
HUMANIGEN, INC's most advanced tracked candidate is ifabotuzumab (Preclinical) for certain solid tumors.
What is HUMANIGEN, INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, HUMANIGEN, INC has approximately 1.6 months of cash runway.
Get the full picture on HUMANIGEN, INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.